首页 | 本学科首页   官方微博 | 高级检索  
检索        

两种单硝酸异山梨酯缓释片在中国健康人体内的生物等效性研究
引用本文:李琴,何艳,陈璐,曾艳,刘琳,张倩,李娜,周岩,刘诗静,杜鹏,曾忱,熊芸.两种单硝酸异山梨酯缓释片在中国健康人体内的生物等效性研究[J].中国医院药学杂志,2022,42(19):2008-2013.
作者姓名:李琴  何艳  陈璐  曾艳  刘琳  张倩  李娜  周岩  刘诗静  杜鹏  曾忱  熊芸
作者单位:1. 贵州医科大学附属医院药物临床试验机构办公室, 贵州 贵阳 550002;2. 遵义医科大学基础药理教育部重点实验室, 贵州 遵义 563006
基金项目:基础药理教育部重点实验室资助项目(编号:黔教合KY字[2022]395号)
摘    要:目的:研究2种单硝酸异山梨酯缓释片在中国健康人体内的药物动力学特征和生物等效性。方法:采用单次给药、随机、开放、两周期、双交叉的试验设计,健康受试者分别在空腹和餐后条件下口服单硝酸异山梨酯缓释片受试制剂与参比制剂各40 mg,利用高效液相色谱-质谱法测定血浆中药物浓度,计算相关药动学参数并评价其生物等效性。结果:(1)空腹试验中受试制剂与参比制剂的Cmax分别为(546.52±102.32),(521.71±85.80)ng·mL-1,AUC0-t分别为(7 398.89±1 298.56),(7 278.29±1 173.38)ng·h·mL-1,AUC0-∞分别为(7 488.82±1 311.38),(7 372.49±1 172.09)ng·h·mL-1。(2)餐后试验中受试制剂与参比制剂的Cmax分别为(529.41±82.52),(502.21±65.15)ng·mL-1,AUC0-t分别为(7 305.10±1 320.74),(7 066.12±1 136.99)ng·h·mL-1,AUC0-∞分别为(7 393.21±1 317.32),(7 160.22±1 140.11)ng·h·mL-1。(3)空腹和餐后试验中受试制剂与参比制剂Cmax、AUC0-t和AUC0-∞几何均数的90%CI均在80.00%~125.00%范围内,表明2种制剂具有生物等效性。结论:单硝酸异山梨酯缓释片受试制剂与参比制剂在中国健康志愿者中具有生物等效性。

关 键 词:单硝酸异山梨酯缓释片  生物等效性  高效液相色谱-质谱法  
收稿时间:2022-03-02

Bioequivalence study of two isosorbide mononitrate sustained-release tablets in Chinese healthy volunteers
LI Qin,HE Yan,CHEN Lu,ZENG Yan,LIU Lin,ZHANG Qian,LI Na,ZHOU Yan,LIU Shi-jing,DU Peng,ZENG Chen,XIONG Yun.Bioequivalence study of two isosorbide mononitrate sustained-release tablets in Chinese healthy volunteers[J].Chinese Journal of Hospital Pharmacy,2022,42(19):2008-2013.
Authors:LI Qin  HE Yan  CHEN Lu  ZENG Yan  LIU Lin  ZHANG Qian  LI Na  ZHOU Yan  LIU Shi-jing  DU Peng  ZENG Chen  XIONG Yun
Institution:1. Office of Drug Clinical Trial Institutions, Affiliated Hospital of Guizhou Medical University, Guizhou Guiyang 550002, China;2. Key Laboratory for Basic Pharmacology of Ministry of Education, Zunyi Medical University, Guizhou Zunyi 563006, China
Abstract:OBJECTIVE To investigate the bioequivalence and pharmacokinetic characteristics of two kinds of isosorbide mononitrate sustained-release tablets in Chinese healthy volunteers.METHODS A randomized, crossover, two periods, and one dose clinical trial was performed in this study. The healthy volunteers were given 40 mg isosorbide mononitrate sustained-release tablets of test (T) and reference (R) preparations respectively under fasting condition and fed condition. The plasma concentration of isosorbide mononitrate was determined by HPLC-MS/MS. Pharmacokinetic parameters of isosorbide mononitrate were calculated and the bioequivalence was evaluated.RESULTS In fasting test, the pharmacokinetic parameters of T and R preparations were as follows:Cmax were (546.52±102.32) and (521.71±85.80) ng·mL-1. AUC0-t were (7 398.89±1 298.56) and (7 278.29±1 173.38) ng·h·mL-1, AUC0-∞ were (7 488.82±1 311.38) and (7 372.49±1 172.09)ng·h·mL-1, respectively. In fed test, the pharmacokinetic parameters of T and R preparations were as follows:Cmax were (529.41±82.52) and (502.21±65.15) ng·mL-1, AUC0-t were (7 305.10±1 320.74) and (7 066.12±1 136.99) ng·h·mL-1, AUC0-∞ were (7 393.21±1 317.32) and (7 160.22±1 140.11) ng·h·mL-1, respectively. In fasting and fed tests, the 90% CI of the geometric mean ratios of Cmax, AUC0-t and AUC0-∞ between T and R preparations were all within the range of 80.00%-125.00%, suggesting the two preparations were bioequivalent.CONCLUSION The two kinds of isosorbide mononitrate sustained-release tablets are bioequivalent in Chinese healthy volunteers.
Keywords:isosorbide mononitrate sustained-release tablets  bioequivalence  HPLC-MS/MS  
点击此处可从《中国医院药学杂志》浏览原始摘要信息
点击此处可从《中国医院药学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号